Mitochondria-targeted antioxidant peptide SS-31 mediates neuroprotection in a rat experimental glaucoma model
Autor: | Chao Wang, Ling Yu, Ai Ling Li, Yu Pang, Zhilin Zhang, Xiaoqiong Wu, Jian Ye, Yingqing Lei, Xiabin Li |
---|---|
Rok vydání: | 2018 |
Předmět: |
Male
Retinal Ganglion Cells Intraocular pressure genetic structures Biophysics Glaucoma Apoptosis Pharmacology Biochemistry Neuroprotection Retinal ganglion Antioxidants Retina Rats Sprague-Dawley 03 medical and health sciences chemistry.chemical_compound medicine Electroretinography Animals Intraocular Pressure 0303 health sciences medicine.diagnostic_test 030302 biochemistry & molecular biology Retinal General Medicine medicine.disease eye diseases Mitochondria Disease Models Animal medicine.anatomical_structure Neuroprotective Agents chemistry sense organs Erg Oligopeptides Injections Intraperitoneal |
Zdroj: | Acta biochimica et biophysica Sinica. 51(4) |
ISSN: | 1745-7270 |
Popis: | To investigate the neuroprotective effects of the mitochondria-targeted antioxidant Szeto-Schiller peptide 31 (SS-31) in a rat experimental glaucoma model, SS-31 was intraperitoneally (IP) injected into Sprague-Dawley rats, followed by intracameral injection of polystyrene microspheres to induce elevated intraocular pressure (IOP). After 6 weeks, electroretinography (ERG) and flash visual-evoked potentials (F-VEPs) were recorded to assess retinal function. Hematoxylin-eosin staining was performed on retinal cross-sections to measure ganglion cell complex (GCC) thickness. Apoptotic retinal cells were assessed by TUNEL staining. Brn3a-positive retinal ganglion cells (RGCs) were counted in retinal flat mounts via immunofluorescence. The retinal total SOD, SOD2, and MDA expression levels were assessed in retinal tissue homogenates. The cyt c, Bax, and Bcl-2 protein levels in rat retinas were detected by western blot analysis. Bax and Bcl-2 expressions were also evaluated using immunohistochemistry in paraffinized sections. Our results showed that the rats that received microsphere injection developed elevated IOP. SS-31 ameliorated the reductions in the a- and b-wave amplitudes on ERG and the F-VEP amplitude in glaucomatous eyes. GCC thickness was preserved, TUNEL-positive cells were decreased in the retina, and Brn3a-positive RGCs were increased in the SS-31-treated glaucoma group compared with those in the non-treated glaucoma group. SS-31 significantly reduced MDA levels and increased SOD2 levels after glaucoma induction. Significant suppression of cyt c release, upregulation of Bcl-2, and downregulation of Bax were observed following SS-31 administration. In summary, SS-31 exerts neuroprotective effects in this experimental glaucoma model by inhibiting mitochondrial dysfunction and therefore represents a promising therapeutic agent for glaucoma. |
Databáze: | OpenAIRE |
Externí odkaz: |